Sep 30, 2021 / 12:40PM GMT
Kristen Kluska - Cantor Fitzgerald, L.P. - Analyst
Hello, everyone. I'm Kristen Kluska, one of the biotechnology analyst at Cantor. It's my pleasure to host Amicus Therapeutics today, which is a company that I'm covering. And joining me on this fireside chat is John Crowley, the Chairman and CEO. Thank you so much for joining us and for being in our conference today.
John Crowley - Amicus Therapeutics, Inc. - Chairman of the Board, CEO
Yes, Kristen, good morning. Thank you for having me.
Questions and Answers:
Kristen Kluska - Cantor Fitzgerald, L.P. - AnalystGreat. So, I'll start the focus of questions on AT-GAA for Pompe disease, especially considering you just announced the FDA acceptance of your filings yesterday. I think it would be helpful to first contextualize the current market centered around current standard of care, Lumizyme. While patients may start treatments at different times of their life at different levels of severity, could you please touch on the trends that have been observed with this
Trustpilot
